Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RBC Capital analyst Ben Hendrix maintained a Buy rating on Amedisys (AMED – Research Report) yesterday and set a price target of $100.00.Stay ...

UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s ...

The United States Justice Department’s lawsuit to block UnitedHealth Group’s (UHG’s) $3.3 billion acquisition of Amedisys ...

A federal judge in Maryland ordered the Justice Department and UnitedHealth Group to begin mediation on Aug. 18.

The U.S. Department of Justice’s (DOJ) lawsuit against Amedisys Inc. (NASDAQ: AMED) and UnitedHealth Group (NYSE: UNH) will ...

Highlights,Geode Capital Management increased its stake in Amedisys during the last quarter.,Major financial institutions have added or expanded positions in Amedisys.,The company posted steady ...

Geode Capital Management LLC Reduces Its Holding in NBT Bancorp Inc. (NASDAQ:NBTB) Highlights,Geode Capital Management increased its stake in Amedisys during the last quarter.,Major financial ...

A long-term study reveals that adhering to a nutritious diet in midlife significantly enhances the likelihood of aging ...